

# Appendix 3Y

## Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

<b>Name of entity</b>	Osteopore Limited
<b>ABN</b>	65 630 538 957

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	Mark Leong
<b>Date of last notice</b>	5 October 2023

### Part 1 - Change of director's relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Direct or indirect interest</b>	Direct and Indirect
<b>Nature of indirect interest (including registered holder)</b> Note: Provide details of the circumstances giving rise to the relevant interest.	Mark Leong <Avalon Partners Pte Ltd A/C> Mark Leong is a Director of Avalon Partners Pte Ltd.
<b>Date of change</b>	4 March 2024
<b>No. of securities held prior to change</b>	<u>Mark Leong</u> 187,500 Fully paid ordinary shares 37,500 Listed Options <u>Mark Leong &lt;Avalon Partners Pte Ltd A/C&gt;</u> 1,000,000 performance rights (Tranche A) 1,500,000 performance rights (Tranche B) 1,750,000 performance rights (Tranche C) 2,250,000 performance rights (Tranche D) 2,750,000 performance rights (Tranche E)

**Appendix 3Y**  
**Change of Director's Interest Notice**

<b>Class</b>	All security classes – Consolidation of capital
<b>Number acquired</b>	N/A – Consolidation of capital
<b>Number disposed</b>	N/A – Consolidation of capital
<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and estimated valuation	N/A – Consolidation of capital
<b>No. of securities held after change</b>	<p><b><u>Mark Leong</u></b></p> <p>12,500 Fully paid ordinary shares 2,500 Listed Options</p> <p><b><u>Mark Leong &lt;Avalon Partners Pte Ltd A/C&gt;</u></b></p> <p>66,667 performance rights (Tranche A) 100,000 performance rights (Tranche B) 116,667 performance rights (Tranche C) 150,000 performance rights (Tranche D) 183,334 performance rights (Tranche E)</p>
<b>Nature of change</b> Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Effect of 15:1 consolidation of capital as approved by shareholders at the General Meeting held on 21 February 2024

**Part 2 – Change of director's interests in contracts**

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

<b>Detail of contract</b>	N/A
<b>Nature of interest</b>	N/A
<b>Name of registered holder (if issued securities)</b>	N/A
<b>Date of change</b>	N/A

+ See chapter 19 for defined terms.

**Appendix 3Y**  
**Change of Director's Interest Notice**

---

<b>No. and class of securities to which interest related prior to change</b> Note: Details are only required for a contract in relation to which the interest has changed	N/A
<b>Interest acquired</b>	N/A
<b>Interest disposed</b>	N/A
<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and an estimated valuation	N/A
<b>Interest after change</b>	N/A

**Part 3 – <sup>+</sup>Closed period**

<b>Were the interests in the securities or contracts detailed above traded during a <sup>+</sup>closed period where prior written clearance was required?</b>	N/A – Consolidation of capital
<b>If so, was prior written clearance provided to allow the trade to proceed during this period?</b>	N/A
<b>If prior written clearance was provided, on what date was this provided?</b>	N/A

---

<sup>+</sup> See chapter 19 for defined terms.

# Appendix 3Y

## Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

<b>Name of entity</b>	Osteopore Limited
<b>ABN</b>	65 630 538 957

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	Teoh Swee Hin
<b>Date of last notice</b>	5 December 2023

### Part 1 - Change of director's relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Direct or indirect interest</b>	Direct and Indirect
<b>Nature of indirect interest (including registered holder)</b> Note: Provide details of the circumstances giving rise to the relevant interest.	BNP Paribas Noms Pty Ltd <UOBKH A/C R'Miers> as custodian for Professor Teoh Swee Hin
<b>Date of change</b>	4 March 2024
<b>No. of securities held prior to change</b>	<p><b><u>Direct: Teoh Swee Hin</u></b></p> <p>100,000 Performance Rights (Tranche A) 150,000 Performance Rights (Tranche B) 175,000 Performance Rights (Tranche C) 225,000 Performance Rights (Tranche D) 275,000 Performance Rights (Tranche E)</p> <p><b><u>Indirect: BNP Paribas Noms Pty Ltd &lt;UOBKH A/C R'Miers&gt; as custodian for Professor Teoh Swee Hin</u></b></p> <p>8,912,886 Fully paid ordinary shares 1,782,577 Listed options</p>

**Appendix 3Y**  
**Change of Director's Interest Notice**

<b>Class</b>	All security classes – Consolidation of capital
<b>Number acquired</b>	N/A – Consolidation of capital
<b>Number disposed</b>	N/A – Consolidation of capital
<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and estimated valuation	N/A – Consolidation of capital
<b>No. of securities held after change</b>	<p><b><u>Direct: Teoh Swee Hin</u></b></p> <p>6,667 Performance Rights (Tranche A) 10,000 Performance Rights (Tranche B) 11,667 Performance Rights (Tranche C) 15,000 Performance Rights (Tranche D) 18,334 Performance Rights (Tranche E)</p> <p><b><u>Indirect: BNP Paribas Noms Pty Ltd &lt;UOBKH A/C R'Miers&gt; as custodian for Professor Teoh Swee Hin</u></b></p> <p>594,192 Fully paid ordinary shares 118,838 Listed options</p>
<b>Nature of change</b> Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Effect of 15:1 consolidation of capital as approved by shareholders at the General Meeting held on 21 February 2024

**Part 2 – Change of director's interests in contracts**

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

<b>Detail of contract</b>	N/A
<b>Nature of interest</b>	N/A
<b>Name of registered holder (if issued securities)</b>	N/A
<b>Date of change</b>	N/A
<b>No. and class of securities to which interest related prior to change</b> Note: Details are only required for a contract in relation to which the interest has changed	N/A

+ See chapter 19 for defined terms.

**Appendix 3Y**  
**Change of Director's Interest Notice**

---

<b>Interest acquired</b>	N/A
<b>Interest disposed</b>	N/A
<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and an estimated valuation	N/A
<b>Interest after change</b>	N/A

**Part 3 – +Closed period**

<b>Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?</b>	N/A – Consolidation of capital
<b>If so, was prior written clearance provided to allow the trade to proceed during this period?</b>	N/A
<b>If prior written clearance was provided, on what date was this provided?</b>	N/A

---

+ See chapter 19 for defined terms.

# Appendix 3Y

## Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

<b>Name of entity</b>	Osteopore Limited
<b>ABN</b>	65 630 538 957

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	Daniel Ow
<b>Date of last notice</b>	5 October 2023

### Part 1 - Change of director's relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Direct or indirect interest</b>	Direct
<b>Nature of indirect interest (including registered holder)</b> Note: Provide details of the circumstances giving rise to the relevant interest.	-
<b>Date of change</b>	4 March 2024
<b>No. of securities held prior to change</b>	<u>Daniel Ow</u>  100,000 performance rights (Tranche A) 150,000 performance rights (Tranche B) 175,000 performance rights (Tranche C) 225,000 performance rights (Tranche D) 275,000 performance rights (Tranche E)

<b>Class</b>	All security classes – Consolidation of capital
<b>Number acquired</b>	N/A – Consolidation of capital
<b>Number disposed</b>	N/A – Consolidation of capital
<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and estimated valuation	N/A – Consolidation of capital
<b>No. of securities held after change</b>	<b><u>Daniel Ow</u></b>  6,667 performance rights (Tranche A) 10,000 performance rights (Tranche B) 11,667 performance rights (Tranche C) 15,000 performance rights (Tranche D) 18,334 performance rights (Tranche E)
<b>Nature of change</b> Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Effect of 15:1 consolidation of capital as approved by shareholders at the General Meeting held on 21 February 2024

## Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

<b>Detail of contract</b>	N/A
<b>Nature of interest</b>	N/A
<b>Name of registered holder (if issued securities)</b>	N/A
<b>Date of change</b>	N/A
<b>No. and class of securities to which interest related prior to change</b> Note: Details are only required for a contract in relation to which the interest has changed	N/A
<b>Interest acquired</b>	N/A

---

+ See chapter 19 for defined terms.

**Appendix 3Y**  
**Change of Director's Interest Notice**

---

<b>Interest disposed</b>	N/A
<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and an estimated valuation	N/A
<b>Interest after change</b>	N/A

**Part 3 - <sup>+</sup>Closed period**

<b>Were the interests in the securities or contracts detailed above traded during a <sup>+</sup>closed period where prior written clearance was required?</b>	N/A - Consolidation of capital
<b>If so, was prior written clearance provided to allow the trade to proceed during this period?</b>	N/A
<b>If prior written clearance was provided, on what date was this provided?</b>	N/A

---

<sup>+</sup> See chapter 19 for defined terms.